- cafead May 23, 2024 at 11:22: AM
via 89bio recently revealed the initiation of the Phase III ENLIGHTEN-Cirrhosis trial of its flagship FGF21 analog, pegozafermin, in patients with metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis. The announcement followed the November release of strong results for pegozafermin in F4 patients, albeit with a very small sample size. Clinical Trials Arena spoke to 89bio’s chief medical officer Hank Mansbach about the news, discussing potential strengths that the asset could have over its competitors.
article source
article source